[Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.]
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Paraneoplastic leukemoid reaction (PLR) is a rare melanoma complication. Targeted therapy with BRAF and MEK inhibitors showed promising results in a patient with BRAF V600E mutated metastatic melanoma and PLR.
Area Of Science
- Oncology
- Dermatology
- Hematology
Background
- Paraneoplastic leukemoid reaction (PLR) is a rare and often prognostically unfavorable condition observed in melanoma patients.
- BRAF mutational analysis is crucial for managing inoperable or metastatic melanoma, guiding targeted therapy selection.
Observation
- This case study details a young woman diagnosed with metastatic melanoma harboring a BRAF V600E mutation.
- The patient also presented with a paraneoplastic leukemoid reaction.
Findings
- The patient was treated with a combination of encorafenib (BRAF inhibitor) and binimetinib (MEK inhibitor).
- The treatment demonstrated a relevant and positive response in managing both the metastatic melanoma and the associated PLR.
Implications
- This case highlights the efficacy of targeted BRAF/MEK inhibition in melanoma patients with rare complications like PLR.
- It underscores the importance of comprehensive molecular profiling for personalized treatment strategies in advanced melanoma.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...